- BioVector NTCC典型培养物保藏中心
- 联系人：Dr.Xu, Biovector NTCC Inc.
电话：400-800-2947 工作QQ:1843439339 (微信同号)
邮件：Biovector@163.com
手机：18901268599
地址：北京
- 已注册
G47ΔBAC plasmid BioVector NTCC质粒载体菌种细胞基因保藏中心
Recombinant oHSVs and viral growth assay. G47ΔBAC contains the genome of G47Δ (γ34.5–, ICP6–, ICP47–) and a cytomegalovirus promoter driven enhanced green fluorescent protein (EGFP) in place of lacZ in G47Δ.17 Recombinant oHSV vectors, G47Δ-empty (oHSV; referred to oHSV in this study), G47Δ-TRAIL (oHSV-TRAIL), and G47Δ-Fluc (oHSV-Fluc), were generated using the methods described previously.25,26,27,50 Briefly, the respective shuttle plasmids were integrated into G47ΔBAC using Cre-mediated recombination in DH10B Escherichia coli, and proper recombination confirmed by restriction analysis of BAC clones. Next, the resulting BAC and an Flpe-expressing plasmid were cotransfected to Vero cells, to remove the BAC-derived sequences and the EGFP gene, and allow virus to be produced. Each recombinant virus was plaque purified and expanded. All the recombinant oHSVs, oHSV, oHSV-TRAIL, and oHSV-Fluc, express E. coli lacZ driven by endogenous ICP6 promoter
Classification: genetically modified oncolytic viral therapy
About Talimogene Laherparepvec (Imlygic™, T-VEC)
Talimogene Laherparepvec is a genetically modified virus. It is a weakened version of the Herpes Simplex Virus Type 1, which can cause cold sores. It replicates within a tumor and produces a protein called GM-CSF that starts an immune response. This causes the lysis (breakdown) of cancer cells.
How to Take Talimogene Laherparepvec
Talimogene Laherparepvec is injected directly into a tumor that is visible or palpable (able to be felt). It can also be injected into a tumor that is detectable with ultrasound guidance. The dose is dependent upon the number of tumors being treated and the size of those tumors. After the initial dose is administered, a second dose will be given 3 weeks later, and a third dose is given 2 weeks after the second dose.
This medication should not be used in patients who are pregnant or have a compromised immune system from HIV, AIDS, blood or bone marrow cancer, autoimmune disease, or who are being treated with steroids. The effectiveness of talimogene laherparepvec can be affected by anti-viral medications, such as acyclovir.
【Supplier来源】BioVector NTCC Inc.
TEL：+86-010-53513060
【Website网址】 http://www.biovector.net
Recombinant oHSVs and viral growth assay. G47ΔBAC contains the genome of G47Δ (γ34.5–, ICP6–, ICP47–) and a cytomegalovirus promoter driven enhanced green fluorescent protein (EGFP) in place of lacZ in G47Δ.17 Recombinant oHSV vectors, G47Δ-empty (oHSV; referred to oHSV in this study), G47Δ-TRAIL (oHSV-TRAIL), and G47Δ-Fluc (oHSV-Fluc), were generated using the methods described previously.25,26,27,50 Briefly, the respective shuttle plasmids were integrated into G47ΔBAC using Cre-mediated recombination in DH10B Escherichia coli, and proper recombination confirmed by restriction analysis of BAC clones. Next, the resulting BAC and an Flpe-expressing plasmid were cotransfected to Vero cells, to remove the BAC-derived sequences and the EGFP gene, and allow virus to be produced. Each recombinant virus was plaque purified and expanded. All the recombinant oHSVs, oHSV, oHSV-TRAIL, and oHSV-Fluc, express E. coli lacZ driven by endogenous ICP6 promoter
Classification: genetically modified oncolytic viral therapy
About Talimogene Laherparepvec (Imlygic™, T-VEC)
Talimogene Laherparepvec is a genetically modified virus. It is a weakened version of the Herpes Simplex Virus Type 1, which can cause cold sores. It replicates within a tumor and produces a protein called GM-CSF that starts an immune response. This causes the lysis (breakdown) of cancer cells.
How to Take Talimogene Laherparepvec
Talimogene Laherparepvec is injected directly into a tumor that is visible or palpable (able to be felt). It can also be injected into a tumor that is detectable with ultrasound guidance. The dose is dependent upon the number of tumors being treated and the size of those tumors. After the initial dose is administered, a second dose will be given 3 weeks later, and a third dose is given 2 weeks after the second dose.
This medication should not be used in patients who are pregnant or have a compromised immune system from HIV, AIDS, blood or bone marrow cancer, autoimmune disease, or who are being treated with steroids. The effectiveness of talimogene laherparepvec can be affected by anti-viral medications, such as acyclovir.
【Supplier来源】BioVector NTCC Inc.
TEL：+86-010-53513060
【Website网址】 http://www.biovector.net
您正在向 biovector.net 发送关于产品 G47ΔBAC plasmid BioVector NTCC质粒载体菌种细胞基因保藏中心 的询问
- 公告/新闻
免费订购电话: 400-800-2947